With more choices for multiple sclerosis (MS) disease-modifying therapies, data are urgently required to support clinical decisions regarding safe transitioning and sequencing of therapies. With more than 7 years of clinical experience, natalizumab has been confirmed as highly effective in reducing MS disease activity. However, natalizumab carries a risk of progressive multifocal leukoencephalopathy (PML), 1 with more than 400 cases of natalizumabrelated PML to date.
When good intentions yield bad outcomes
With more choices for multiple sclerosis (MS) disease-modifying therapies, data are urgently required to support clinical decisions regarding safe transitioning and sequencing of therapies. With more than 7 years of clinical experience, natalizumab has been confirmed as highly effective in reducing MS disease activity. However, natalizumab carries a risk of progressive multifocal leukoencephalopathy (PML), 1 with more than 400 cases of natalizumabrelated PML to date. 2 Because 2 of the 3 initial natalizumab-associated PML cases were on the combination natalizumab plus interferon, the concern was that combining agents led to a heightened risk of infectious complications. In these early times, uncertainty revolved around 2 points: the theoretical risk of PML if natalizumab was transiently combined with another immune-altering agent and the value of transiently "reconstituting" CNS immune surveillance by washout of natalizumab in an effort to clear theoretical subclinical JC virus within the CNS. 3 The optimal length of natalizumab washout became the subject of intense consternation and debate, with no clear guidelines to inform practice. However, upon withdrawing natalizumab, resumption of disease activity was soon observed, beginning 3-4 months after the last dose of natalizumab. [4] [5] [6] [7] [8] [9] [10] Postnatalizumab return of disease raised concern that the washout may harm the patient by a severe relapse with incomplete recovery.
In this issue of Neurology ® , Jokubaitis et al. 11 provide valuable data on switching between therapies using real-world data from the MSBase register. MSBase is a collaborative database dedicated to evaluating outcomes data in MS, with 24,898 patients from 183 clinics based in 66 countries. [11] [12] [13] [14] MSBase investigators studied 536 patients who started fingolimod, 89 of whom were switched from natalizumab. The median washout period from the last infusion was 79 days, and prophylactic methylprednisolone was used for only 1 patient. Of patients transitioned to fingolimod, 20% relapsed after stopping natalizumab, with relapses equally distributed within the first, second, and third trimester after discontinuation.
Patients with a clinical relapse within the final 6 months of natalizumab treatment had an increased relative risk of a postswitch relapse of 1.6 (95% confidence interval [CI] 1.19-2.13). Stratified by washout durations, patients had a 2.12 (95% CI 1.04-4.32) relative risk of a postswitch relapse with a 2-to 4-month treatment washout compared to the no washout gap and a nonsignificant relapse risk of 1.54 (95% CI 0.92-2.59) with a washout gap of ,2 months vs no washout gap.
This study by Jokubaitis et al. adds to an emerging literature suggesting that a prolonged washout does more harm than good. Rinaldi et al. 15 observed 22 patients with relapsing-remitting MS who were switched from natalizumab to fingolimod. For patients who underwent a 3-month washout period, 50% had a clinical relapse or new MRI activity. A French study of 59 patients who switched from natalizumab to fingolimod reported that 50% of patients had a relapse with a washout of 3 or more months, compared to 7% of patients who had a relapse with a washout of less than 3 months. 16 Novartis, the manufacturer of fingolimod, investigated the effect of different natalizumab washout periods on clinical and MRI disease activity in 142 patients switching from natalizumab to fingolimod. 17 This double-blind placebo-controlled trial randomized patients with relapsing-remitting MS within 7 days after the last natalizumab infusion to 8, 12, or 16 weeks washout before starting fingolimod. Brain MRI was performed at baseline and weeks 8, 12, 16, 20, and 24. Mean number of active MRI lesions from the last natalizumab infusion was markedly increased with the 16-week washout (8.2 lesions) compared to the 8-and 12-week washouts (2.1 and 1.7 lesions). More patients demonstrated freedom from gadolinium-enhancing lesions on the week 24 MRI with shorter washout periods (75% with the 8-week washout, 61.3% with the 12-week washout, and 47.5% with the 16-week washout). Annualized relapse rates after switching were higher with the 16-week washout (0.36 with 8-week washout, 0.33 with 12-week washout, 0.65 with 16-week washout). These emerging data tell a consistent story that any washout should be kept to a minimum and should be no longer than 2 months-at least with fingolimod-with some studies suggesting that no washout is optimal. The pharmacodynamics of the next agent to become clinically effective are also critical so that efficacy is achieved before natalizumab saturation of VLA4 falls to a level that allows trafficking of lymphocytes back into the CNS. Hence, recommendations based on fingolimod may not necessarily be similar for other agents, for example with dimethyl fumarate and glatiramer acetate. Glatiramer acetate may need to be started prior to stopping natalizumab, as it has a delayed onset of action.
How do we apply these studies to clinical practice? Currently, the evidence-based harm of a breakthrough relapse causing sustained disability outweighs the theoretical concern that overlapping therapies will result in more PML.
These studies indicate that fingolimod, when start-up is properly timed, can be effective postnatalizumab. Patients who switch from natalizumab to fingolimod with a washout period of 2 months or less have a lower risk of rebound and an even lower risk with no washout period, i.e., less than 4 weeks. While we have experience with and data on converting patients from natalizumab to fingolimod or an injectable disease-modifying therapy, we are still acquiring experience with the efficacy and safety of newer agents (i.e., dimethylfumarate, teriflunomide) and have virtually no experience with switching from natalizumab to emerging monoclonal antibodies with prolonged consequences on the immune system (i.e., alemtuzumab, daclizumab, ocrelizumab). As Jokubaitis et al. clearly demonstrate, patient registries such as MSBase, along with industry-sponsored switching studies, will be required to provide necessary data tailored to the therapeutic agent and patient scenario.
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